N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol
C18H22F2N6O3 — CID 156823602
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol
N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol (PubChem CID 156823602) has the molecular formula C18H22F2N6O3 and a molecular weight of 408.41 g/mol. Its IUPAC name is N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol.
Molecular Properties
| Compound Name | N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol |
|---|---|
| PubChem CID | 156823602 |
| Molecular Formula | C18H22F2N6O3 |
| Molecular Weight | 408.41 g/mol |
| Exact Mass | 408.17 |
| IUPAC Name | N-[1-cyclohexyl-3-(difluoromethoxy)pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;methanol |
| SMILES | CO.O=C(Nc1cn(C2CCCCC2)nc1OC(F)F)c1cnn2cccnc12 |
| InChI | InChI=1S/C17H18F2N6O2.CH4O/c18-17(19)27-16-13(10-25(23-16)11-5-2-1-3-6-11)22-15(26)12-9-21-24-8-4-7-20-14(12)24;1-2/h4,7-11,17H,1-3,5-6H2,(H,22,26);2H,1H3 |
| InChIKey | QSRKDCWEFLXFJH-UHFFFAOYSA-N |
| XLogP | 2.89 |
| TPSA | 106.57 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 408.41 |
| LogP ≤ 5 | 2.89 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156823602 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.